-
公开(公告)号:US20240002843A1
公开(公告)日:2024-01-04
申请号:US17965366
申请日:2022-10-13
Applicant: Novartis AG , Intellia Therapeutics, Inc.
Inventor: Anthony Edward BOITANO , Michael COOKE , Lloyd B. KLICKSTEIN , Reynald LESCARBEAU , Craig Stephen MICKANIN , Kabungo MULUMBA , Seshidhar Reddy POLICE , Jennifer SNEAD , Susan C. STEVENSON , Morag STEWART , Yi YANG
IPC: C12N15/113 , A61K35/15 , A61P7/00
CPC classification number: C12N15/113 , A61K35/15 , A61P7/00 , C12N2310/315 , C12N2310/322 , C12N2310/10 , C12N2310/321 , C12N2310/20
Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
-
公开(公告)号:US20250127809A1
公开(公告)日:2025-04-24
申请号:US18569029
申请日:2022-06-22
Applicant: Novartis AG
Inventor: Muluken Shambel BELEW , Jennifer Stroka COBB , Carsten RUSS , Frederic SIGOILLOT , Susan C. STEVENSON , Pamela YF TING
Abstract: The present invention is directed to compositions and methods for the treatment of hemoglobinopathies.
-
公开(公告)号:US20230279394A1
公开(公告)日:2023-09-07
申请号:US17786347
申请日:2020-12-16
Applicant: Novartis AG
Inventor: Muluken BELEW , Simone BONAZZI , James BRADNER , Artiom CERNIJENKO , Jennifer Stroka COBB , Natalie DALES , John Ryan KERRIGAN , Philip LAM , Hasnain Ahmed MALIK , Carsten RUSS , Frederic SIGOILLOT , Susan C. STEVENSON , Noel Marie-France THOMSEN , Pamela TING
IPC: C12N15/113 , C12N15/86 , C12N5/07 , A61P7/00
CPC classification number: C12N15/113 , A61P7/00 , C12N5/06 , C12N15/86 , C12N2310/20
Abstract: The present invention is directed to compositions and methods for the treatment of hemoglobinopathies.
-
公开(公告)号:US20190010495A1
公开(公告)日:2019-01-10
申请号:US16066617
申请日:2016-12-26
Applicant: NOVARTIS AG , INTELLIA THERAPEUTICS, INC.
Inventor: Anthony Edward BOITANO , Michael COOKE , Lloyd B. KLICKSTEIN , Reynald LESCARBEAU , Craig Stephen MICKANIN , Kabungo MULUMBA , Seshidhar Reddy POLICE , Jennifer SNEAD , Susan C. STEVENSON , Morag STEWART , Yi YANG
IPC: C12N15/113 , A61P7/00 , A61K35/15
Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
-
-
-